**WHRI Website:**

**Research Project Template**

Please complete one form per research project/program you would like displayed on the WHRI website. This page will provide you with a space to help recruit participants, disseminate findings and showcase other knowledge translation activities resulting from the study. The content you provide in this form will be connected to the research team’s bios provided by the membership information. If any of these fields do not apply to this project, please leave them blank.

If there are supporting documents you would like embedded on the project page (i.e. consent forms) or if you have any questions regarding this form, please contact Nicole Prestley at [Nicole.Prestley@cw.bc.ca](mailto:Nicole.Prestley@cw.bc.ca) or by phone **604-875-2424 ext 4956**.

|  |  |
| --- | --- |
| **Title:**  (same as consent form) | CARMA 7: Bone and Renal Outcomes in HIV-Exposed, Uninfected Infants with Perinatal Exposure to Tenofovir |
| **Principal Investigator:** | Dr. Ariane Alimenti |
| **Primary Contact:**  (name, title, phone, email) | Evelyn Maan, Research Manager, 604-875-2000 ext. 2463, emaan@cw.bc.ca |
| **About the Study:**  (100 words or less plain language summary) | Anti-HIV medication has reduced the risk of HIV transmission from mother to child from 25% to less than 1%. However, the effects of some of these anti-HIV medications on the developing fetus have not yet been thoroughly studied. One medication in particular, called “Tenofovir”, can cause some bone and kidney problems for HIV+ adults when taken for a long time, especially with existing bone and kidney diseases. The purpose of CARMA 7 is to investigate how fetal exposure to Tenofovir may affect the bone and kidney health of infants who are born to HIV+ women. |
| **Why is this research important?** | The use of Tenofovir is becoming far more common in anti-HIV medication regimens because it is so well tolerated. As a result, an increasing number of women are getting pregnant while taking this particular medication (almost 25% of HIV+ pregnancies in BC in 2011). Accordingly, it is very important for the current and future health of infants born to HIV+ women to study the effects of this anti-HIV medication. |
| **Study Status:**  (e.g. recruiting, data analysis, manuscript development, complete) | Recruiting |
| **Who can participate:**  (short description, attach consent form) | Infants who do not have HIV, born at term (>35 weeks +2 days) to an HIV+ mother who took anti-HIV medication during her pregnancy, specifically Tenofovir, Abacavir, or Zidovudine (the last two for the control group).  Infants have visits for the CARMA-7 study at 1 month, 6 months, and 18 months of age. |
| **Study Results/Publication:** |  |
| **Co-Investigators:** | Dr. Helene Cote, Dr. Deborah Money, Dr. Laura Sauve, Dr. Jason Brophy |
| **Funded by:** | CIHR, Canadian HIV Trials Network |
| **Partners:** |  |
| **Other Attachments:**  (e.g. Newsletters, videos) |  |